TVB-2640 (denifanstat), which inhibits FASN β-ketoacyl reductase activity, is the most clinically advanced FASN inhibitor (94), and it is currently in clinical trials for the treatment of metabolic disorders, several cancers, and dermatology indications. This evidence concerns the gene FASN and cancer.